Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) insider Derek J. Maetzold sold 2,188 shares of the company's stock in a transaction on Monday, September 26th. The stock was sold at an average price of $23.93, for a total value of $52,358.84. Following the sale, the insider now owns 306,075 shares of the company's stock, valued at $7,324,374.75. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Castle Biosciences Stock Performance

Shares of NASDAQ CSTL traded up $2.31 during midday trading on Wednesday, hitting $26.09. The stock had a trading volume of 246,420 shares, compared to its average volume of 284,220. The stock has a 50 day simple moving average of $28.95 and a 200-day simple moving average of $27.40. Castle Biosciences, Inc. has a 1 year low of $15.58 and a 1 year high of $68.65.

Castle Biosciences (NASDAQ:CSTL – Get Rating) last posted its earnings results on Monday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.52. The company had revenue of $34.84 million during the quarter, compared to analysts' expectations of $28.40 million. Castle Biosciences had a negative return on equity of 9.81% and a negative net margin of 40.37%. During the same quarter last year, the firm earned ($0.34) earnings per share. As a group, equities research analysts anticipate that Castle Biosciences, Inc. will post -2.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Lazard Asset Management LLC purchased a new position in Castle Biosciences in the first quarter valued at $57,000. Captrust Financial Advisors lifted its holdings in Castle Biosciences by 762.2% during the 2nd quarter. Captrust Financial Advisors now owns 4,018 shares of the company's stock worth $88,000 after buying an additional 3,552 shares during the last quarter. Amalgamated Bank purchased a new stake in Castle Biosciences during the 1st quarter worth about $152,000. PNC Financial Services Group Inc. lifted its holdings in Castle Biosciences by 52.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,745 shares of the company's stock worth $168,000 after buying an additional 1,290 shares during the last quarter. Finally, First Bank & Trust lifted its holdings in Castle Biosciences by 90.2% during the 2nd quarter. First Bank & Trust now owns 7,818 shares of the company's stock worth $172,000 after buying an additional 3,708 shares during the last quarter. 86.08% of the stock is currently owned by hedge funds and other institutional investors.

Castle Biosciences Company Profile

(Get Rating)

Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.

Further Reading

• Get a free copy of the StockNews.com research report on Castle Biosciences (CSTL)
• Can United Natural Foods Fight Both Inflation and the Fed?
• Mullen Automotive Is Ready To Get In Gear
• Cracker Barrel: A Tasty Treat Or Bad Apple?
• Defensive Stocks For A Volatile Market
• SunPower Is Ready To Power Up Triple-Digit Earnings Gains

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.